Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

July 31, 2026

Consolidated Financial Results for the Three Months Ended June 30, 2026 (Under Japanese GAAP)

Company name: Kitazato Corporation
Listing: Tokyo Stock Exchange
Securities code: 368A
URL: https://www.kitazato.co.jp
Representative: Futoshi Inoue, President, CEO
Inquiries: Masanobu Suzuki, Director, General Manager of Corporate Planning Department
Telephone: +81-545-65-7122
Scheduled date to commence dividend payments: –
Preparation of supplementary material on financial results: Yes
Holding of financial results briefing: Yes (for institutional investors and analysts)

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the three months ended June 30, 2026 (from April 1, 2026 to June 30, 2026)

(1) Consolidated operating results (cumulative) (Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Three months ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
June 30, 2026	3,017	24.0	1,517	27.0	1,535	36.5	1,007	35.1
June 30, 2025	2,434	3.6	1,195	(4.2)	1,125	(11.1)	745	(9.3)

Note: Comprehensive income For the three months ended June 30, 2026:¥1,007 million [35.1%]
For the three months ended June 30, 2025:¥ 745 million [(9.3)%]

	Basic earnings per share	Diluted earnings per share
Three months ended	Yen	Yen
June 30, 2026	25.18	–
June 30, 2025	18.64	–

(2) Consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio
As of	Millions of yen	Millions of yen	%
June 30, 2026	20,995	19,871	94.6
March 31, 2026	21,996	20,504	93.2

Reference: Equity
As of June 30, 2026: ¥19,871 million
As of March 31, 2026: ¥20,504 million

2. Cash dividends

	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2026	–	0.00	–	41.00	41.00
Fiscal year ending March 31, 2027	–				
Fiscal year ending March 31, 2027 (Forecast)		0.00	–	41.00	41.00

Note: Revisions to the forecast of cash dividends most recently announced: None

3. Consolidated financial results forecasts for the fiscal year ending March 31, 2027 (from April 1, 2026 to March 31, 2027)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full year	11,346	3.6	6,115	4.4	6,137	4.0	4,059	4.2	101.50

Note: Revisions to the forecast of financial results most recently announced: None

* **Notes**

(1) Significant changes in the scope of consolidation during the period: None

(2) Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements: Yes

Note: For details, please see page 8 of the Attachments: "2. Quarterly Consolidated Financial Statements and Principal Notes (3) Notes to Quarterly Consolidated Financial Statements (Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements)."

(3) Changes in accounting policies, changes in accounting estimates, and restatement

(i) Changes in accounting policies due to revisions to accounting standards and other regulations: None

(ii) Changes in accounting policies due to other reasons: None

(iii) Changes in accounting estimates: None

(iv) Restatement: None

(4) Number of issued shares (common shares)

(i) Total number of issued shares at the end of the period (including treasury shares)

As of June 30, 2026	40,000,000 shares
As of March 31, 2026	40,000,000 shares

(ii) Number of treasury shares at the end of the period

As of June 30, 2026	– shares
As of March 31, 2026	– shares

(iii) Average number of shares outstanding during the period (cumulative from the beginning of the fiscal year)

Three months ended June 30, 2026	40,000,000 shares
Three months ended June 30, 2025	40,000,000 shares

* Review of the Japanese-language originals of the attached consolidated quarterly financial statements by certified public accountants or an audit firm: Yes (voluntary)

* Proper use of earnings forecasts, and other special matters

(Notes on forward-looking statements)

The financial results forecasts and other forward-looking statements contained in these documents are based on information currently available to the Company and certain assumptions that the Company has deemed reasonable. The information is not intended as a guarantee that the Company will achieve these targets. Actual financial results may differ significantly due to various factors.

(Change of Trade Name)

Effective July 1, 2026, the Company changed its Japanese corporate name, while retaining "Kitazato Corporation" as its English corporate name.

Table of Contents - Attachments

1. Overview of Operating Results and Financial Position.

(1) Overview of Operating Results for the Three Months Ended June 30, 2026

During the three months ended June 30, 2026 (from April 1, 2026 to June 30, 2026), the Japanese economy remained on a gradual recovery trend, supported by improvements in the employment and income environment. Meanwhile, uncertainty continued in the global economy, as developments in trade policies, including US tariff policies, and the situation in the Middle East affected financial and capital markets and corporate activities.

In the fertility treatment field, in which the Kitazato Group operates, demand continued to expand both in Japan and overseas, driven by the trend toward later marriage and childbearing, as well as growing social awareness of fertility treatment. In Japan, the environment surrounding fertility treatment and related fields continued to improve, with an increase in the number of medical institutions providing assisted reproductive technology and the enhancement of public support, including subsidies for oocyte cryopreservation. Overseas, the fertility treatment market is also expected to expand over the medium to long term, driven by the enhancement of support programs and healthcare delivery systems.

Under these circumstances, the Kitazato Group worked to strengthen its overseas operating base, launch new and improved products, accumulate intellectual property, and enhance its production and supply systems. In June 2026, the Group announced a medium-term management plan positioned as the first stage of its long-term vision, “Kitazato Challenge 2036,” and is promoting initiatives aimed at achieving sustainable growth in existing businesses and building a foundation for future growth.

Effective July 1, 2026, the Company changed its Japanese corporate name. Under the new corporate name, the Group will work together to realize its corporate philosophy, “Happiness, for the Next Generations – Bringing Smiles to Future Generations.”

The Group’s consolidated financial results for the three months ended June 30, 2026 are as follows.

<Net sales>

The Group’s net sales for the three months ended June 30, 2026 amounted to ¥3,017 million, an increase of 24.0% year on year.

In Japan, in addition to stable growth in demand, one-off orders arose due to concerns over the impact of the situation in the Middle East. As a result, net sales amounted to ¥993 million (up 10.9% year on year).

Overseas, net sales amounted to ¥2,024 million (up 31.6% year on year), reflecting sales growth in Europe, the U.S., and other regions.

By product category, new products launched in the previous fiscal year contributed to sales growth in Media and Medical Device. Demand for Cryodevice remained firm both in Japan and overseas, while demand for Micro Tools remained robust mainly in Europe and the U.S. As a result, net sales in all product categories increased from the same period of the previous fiscal year.

[Net sales by region]

(Millions of Yen)

	First quarter of the fiscal year ended March 31, 2026 (results)	First quarter of the fiscal year ending March 31, 2027 (results)	Change	Percentage change
Net sales	2,434	3,017	583	124.0%
Japan	895	993	98	110.9%
Overseas	1,538	2,024	485	131.6%
Europe	844	1,135	290	134.5%
U.S.	242	317	74	130.8%
China	133	126	(6)	95.0%

India	145	154	9	106.2%
Other	173	290	117	167.9%

[Net sales by product category]

(Millions of Yen)

	First quarter of the fiscal year ended March 31, 2026 (results)	First quarter of the fiscal year ending March 31, 2027 (results)	Change	Percentage change
Net sales	2,434	3,017	583	124.0%
Media	923	1,071	147	116.0%
Cryodevice	563	810	246	143.7%
Medical Device	606	707	100	116.5%
Micro Tools	282	362	79	128.0%
Other	56	66	9	117.4%

<Profit>

Gross profit amounted to ¥1,886 million (up 20.2% year on year), mainly due to an increase in net sales, partly offset by an increase in the cost of sales ratio due to a change in the product mix.

Operating profit amounted to ¥1,517 million (up 27.0% year on year), reflecting an increase in gross profit and a year-on-year decrease in selling, general and administrative expenses.

Ordinary profit amounted to ¥1,535 million (up 36.5% year on year), reflecting foreign exchange gains and the absence of listing-related expenses recorded in the same period of the previous fiscal year.

As a result, profit attributable to owners of parent amounted to ¥1,007 million, an increase of 35.1% year on year.

(2) Overview of Financial Position for the Three Months Ended June 30, 2026

Total assets as of June 30, 2026 amounted to ¥20,995 million, a decrease of ¥1,001 million compared with the end of the previous consolidated fiscal year. This was mainly due to a decrease of ¥902 million in cash and deposits.

Total liabilities amounted to ¥1,123 million, a decrease of ¥368 million compared with the end of the previous consolidated fiscal year. This was mainly due to a decrease of ¥423 million in income taxes payable.

Total net assets amounted to ¥19,871 million, a decrease of ¥632 million compared with the end of the previous consolidated fiscal year. This was due to a dividend payment of ¥1,640 million, offset by the recording of ¥1,007 million in profit attributable to owners of parent.

(3) Explanation of Consolidated Financial Results Forecast and Other Forward-looking Information

The consolidated financial results forecast for the fiscal year ending March 31, 2027 remains unchanged from the forecast announced on April 30, 2026.

2. Quarterly Consolidated Financial Statements and Principal Notes

(1) Quarterly Consolidated Balance Sheet

(Millions of yen)

	As of March 31, 2026	As of June 30, 2026
Assets		
Current assets		
Cash and deposits	13,414	12,512
Accounts receivable - trade	1,561	1,304
Merchandise and finished goods	399	349
Work in process	597	588
Raw materials and supplies	1,003	1,069
Other	170	297
Total current assets	17,147	16,122
Non-current assets		
Property, plant and equipment		
Buildings and structures	2,933	2,933
Machinery, equipment and vehicles	261	321
Land	2,024	2,024
Other	466	472
Accumulated depreciation	(1,103)	(1,151)
Total property, plant and equipment	4,582	4,601
Intangible assets		
Other	47	46
Total intangible assets	47	46
Investments and other assets		
Deferred tax assets	108	112
Other	110	112
Total investments and other assets	219	225
Total non-current assets	4,849	4,872
Total assets	21,996	20,995

(Millions of yen)

	As of March 31, 2026	As of June 30, 2026
Liabilities		
Current liabilities		
Accounts payable - trade	187	212
Income taxes payable	958	535
Provision for bonuses	60	67
Provision for product warranties	7	7
Other	216	252
Total current liabilities	1,430	1,075
Non-current liabilities		
Other	61	48
Total non-current liabilities	61	48
Total liabilities	1,491	1,123
Net assets		
Shareholders’ equity		
Share capital	10	10
Retained earnings	20,494	19,861
Total shareholders’ equity	20,504	19,871
Total net assets	20,504	19,871
Total liabilities and net assets	21,996	20,995

(2) Quarterly Consolidated Statements of Income and Comprehensive Income

Quarterly Consolidated Statement of Income

Three Months Ended June 30

(Millions of yen)

	For the three months ended June 30, 2025	For the three months ended June 30, 2026
Net sales	2,434	3,017
Cost of sales	865	1,131
Gross profit	1,568	1,886
Selling, general and administrative expenses	373	368
Operating profit	1,195	1,517
Non-operating income		
Interest income	0	5
Foreign exchange gains	-	13
Other	1	0
Total non-operating income	1	18
Non-operating expenses		
Interest expenses	0	0
Foreign exchange losses	20	-
Listing expenses	49	-
Total non-operating expenses	70	0
Ordinary profit	1,125	1,535
Extraordinary income		
Gain on sale of non-current assets	0	-
Total extraordinary income	0	-
Profit before income taxes	1,126	1,535
Income taxes - current	384	532
Income taxes - deferred	(3)	(3)
Total income taxes	380	528
Profit	745	1,007
Profit attributable to owners of parent	745	1,007

Quarterly Consolidated Statement of Comprehensive Income

Three Months Ended June 30

(Millions of yen)

	For the three months ended June 30, 2025	For the three months ended June 30, 2026
Profit	745	1,007
Comprehensive income	745	1,007
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	745	1,007

(3) Notes to Quarterly Consolidated Financial Statements

The quarterly consolidated financial statements have been prepared in accordance with Article 4, Paragraph 1 of the Standards for Preparation of Quarterly Financial Statements, etc. of the Tokyo Stock Exchange, Inc. and accounting standards for quarterly financial statements that are generally accepted in Japan (provided, however, that the omission of a statement prescribed in Article 4, Paragraph 2 of the Standards for Preparation of Quarterly Financial Statements, etc. has been applied).

(Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements)

(Calculation of tax expenses)

Regarding tax expenses, the Company reasonably estimates an effective tax rate after applying tax effect accounting to profit before income taxes for the fiscal year that includes the first quarter of the fiscal year ending March 31, 2027, and calculates tax expenses by multiplying quarterly profit before income taxes by such estimated effective tax rate. However, if the estimated effective tax rate cannot be used, the statutory effective tax rate is used instead.

(Notes on segment information, etc.)

Segment information has been omitted as the Group operates only a single segment in the medical device business.

(Notes in case of significant changes in shareholders’ equity)

Not applicable.

(Notes on going concern assumption)

Not applicable.

(Notes on statement of cash flow)

The Company has not prepared a quarterly consolidated statement of cash flow for the three months ended June 30, 2026. Depreciation (including amortization related to intangible assets) for the three-month ended June 30 is as follows.

	For the three months ended June 30, 2025	For the three months ended June 30, 2026
Depreciation	¥43 million	¥52 million